Stocks · News reference
JP Morgan analyst Chris Schott maintains Merck & Co (NYSE:MRK) with a Overweight and raises the price target from $150 to $165.
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Vaccine stocks are trending on Tuesday. Shares of Moderna Inc. (NASDAQ:MRNA), Vaxcyte Inc. (NASDAQ:PCVX) and Novavax Inc. (NASDAQ:NVAX) are moving in the after-hours session on Monday. Moderna rose 0.17% to
Eight sectors are higher and three are lower in Monday's regular session, with growth, cyclical and defensive sectors split across the top three positions. The leaders are separated rather than clustered.
Vaxcyte announced positive Phase 3 OPUS-1 trial results for its VAX-31 vaccine candidate, setting the stage for an FDA BLA filing.